L. O. White

1.0k total citations
33 papers, 749 citations indexed

About

L. O. White is a scholar working on Pharmacology, Molecular Medicine and Infectious Diseases. According to data from OpenAlex, L. O. White has authored 33 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pharmacology, 8 papers in Molecular Medicine and 7 papers in Infectious Diseases. Recurrent topics in L. O. White's work include Antibiotics Pharmacokinetics and Efficacy (21 papers), Antibiotic Resistance in Bacteria (8 papers) and Bacterial Identification and Susceptibility Testing (6 papers). L. O. White is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (21 papers), Antibiotic Resistance in Bacteria (8 papers) and Bacterial Identification and Susceptibility Testing (6 papers). L. O. White collaborates with scholars based in United Kingdom, United States and Austria. L. O. White's co-authors include H. A. Holt, D. S. Reeves, M. J. Bywater, D. S. Reeves, Alasdair MacGowan, A. M. Lovering, John P. Leeming, Jeremy P. Diamond, D L Easty and H B Hoh and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, TrAC Trends in Analytical Chemistry and Journal of Antimicrobial Chemotherapy.

In The Last Decade

L. O. White

33 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. O. White United Kingdom 18 426 217 209 100 94 33 749
G. Humbert France 20 528 1.2× 242 1.1× 283 1.4× 145 1.4× 66 0.7× 75 976
Neu Hc United States 12 275 0.6× 215 1.0× 135 0.6× 77 0.8× 66 0.7× 41 520
P Aswapokee United States 10 407 1.0× 332 1.5× 275 1.3× 115 1.1× 69 0.7× 19 773
J. Kosmidis Greece 17 296 0.7× 206 0.9× 294 1.4× 151 1.5× 68 0.7× 47 794
F. Faurisson France 13 171 0.4× 135 0.6× 158 0.8× 90 0.9× 82 0.9× 26 773
G. K. Daikos Greece 16 252 0.6× 175 0.8× 209 1.0× 140 1.4× 76 0.8× 63 648
C H Nightingale United States 17 657 1.5× 325 1.5× 427 2.0× 192 1.9× 76 0.8× 37 1.0k
H. A. Holt United Kingdom 21 720 1.7× 568 2.6× 397 1.9× 229 2.3× 136 1.4× 54 1.2k
P. Schacht Germany 9 369 0.9× 123 0.6× 174 0.8× 47 0.5× 60 0.6× 15 550
C Regamey Switzerland 19 718 1.7× 300 1.4× 401 1.9× 276 2.8× 147 1.6× 56 1.3k

Countries citing papers authored by L. O. White

Since Specialization
Citations

This map shows the geographic impact of L. O. White's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. O. White with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. O. White more than expected).

Fields of papers citing papers by L. O. White

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. O. White. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. O. White. The network helps show where L. O. White may publish in the future.

Co-authorship network of co-authors of L. O. White

This figure shows the co-authorship network connecting the top 25 collaborators of L. O. White. A scholar is included among the top collaborators of L. O. White based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. O. White. L. O. White is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bonatti, Hugo, David Nachbaur, Manfred Fille, et al.. (2003). A series of Infections due to Capnocytophaga spp. in immunosuppressed and immunocompetent patients. Clinical Microbiology and Infection. 9(5). 380–387. 42 indexed citations
2.
White, L. O.. (2000). UK NEQAS in antibiotic assays. Journal of Clinical Pathology. 53(11). 829–834. 5 indexed citations
3.
Brown, N. M., et al.. (1997). The pharmacokinetics of once-daily oral 400 mg ofloxacin in patients with peritonitis complicating continuous ambulatory peritoneal dialysis. Journal of Antimicrobial Chemotherapy. 39(6). 829–831. 2 indexed citations
4.
MacGowan, Alasdair, et al.. (1997). External quality assessment of the serum bactericidal test: results of a methodology/interpretation questionnaire. Journal of Antimicrobial Chemotherapy. 39(2). 277–284. 12 indexed citations
5.
Lovering, A. M., L. O. White, Alasdair MacGowan, & D. S. Reeves. (1996). The elution and binding characteristics of rifampicin for three commercially available protein-sealed vascular grafts. Journal of Antimicrobial Chemotherapy. 38(4). 599–604. 9 indexed citations
6.
White, L. O., et al.. (1996). The quality of clinical serum teicoplanin assays: an experimental European EQA distribution. Journal of Antimicrobial Chemotherapy. 38(4). 701–706. 8 indexed citations
7.
Reeves, D. S., et al.. (1995). Therapeutic monitoring of antimicrobials: a summary of the information presented at the UK NEQAS for Antibiotic Assays meeting for participants, October 1993. Journal of Antimicrobial Chemotherapy. 35(1). 213–226. 15 indexed citations
8.
Lovering, A. M., Christopher Vickery, D J Leaper, et al.. (1995). The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. Journal of Antimicrobial Chemotherapy. 36(1). 165–172. 26 indexed citations
9.
Diamond, Jeremy P., L. O. White, John P. Leeming, H B Hoh, & D L Easty. (1995). Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.. British Journal of Ophthalmology. 79(6). 606–609. 66 indexed citations
10.
11.
Brown, N. M., et al.. (1993). Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. Journal of Antimicrobial Chemotherapy. 32(1). 117–122. 18 indexed citations
12.
Johnson, Elizabeth J., Alasdair MacGowan, Mike Potter, et al.. (1990). Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. Journal of Antimicrobial Chemotherapy. 25(5). 837–842. 30 indexed citations
13.
Ludlam, H., et al.. (1990). Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). Journal of Antimicrobial Chemotherapy. 25(5). 843–851. 29 indexed citations
14.
Lovering, A. M., et al.. (1989). Pharmacokinetics of FCE 22101 in man following different modes of administration. Journal of Antimicrobial Chemotherapy. 23(suppl C). 179–195. 5 indexed citations
15.
Humphreys, H., et al.. (1989). Flavobacterium meningosepticum infection, in a 32-day-old child on acute peritoneal dialysis, treated with ciprofloxacin. Journal of Antimicrobial Chemotherapy. 23(2). 292–294. 8 indexed citations
16.
MacGowan, Alasdair, et al.. (1988). The pharmacokinetics of norfloxacin in the aged. Journal of Antimicrobial Chemotherapy. 22(5). 721–727. 12 indexed citations
17.
White, L. O., et al.. (1988). The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. Journal of Antimicrobial Chemotherapy. 22(Supplement_C). 65–72. 12 indexed citations
18.
White, L. O., Richard Edwards, H. A. Holt, et al.. (1988). The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. Journal of Antimicrobial Chemotherapy. 22(5). 739–745. 35 indexed citations
19.
20.
White, L. O.. (1986). The development of microbiological and immunological assays for antibiotics. TrAC Trends in Analytical Chemistry. 5(2). 29–31. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Humbert Breakdown of academic impact, for papers by Neu Hc Breakdown of academic impact, for papers by P Aswapokee Breakdown of academic impact, for papers by J. Kosmidis Breakdown of academic impact, for papers by F. Faurisson Breakdown of academic impact, for papers by G. K. Daikos Breakdown of academic impact, for papers by C H Nightingale Breakdown of academic impact, for papers by H. A. Holt Breakdown of academic impact, for papers by P. Schacht Breakdown of academic impact, for papers by C Regamey
Rankless by CCL
2026